share_log

Ginkgo Bioworks | 10-Q: Quarterly report

Ginkgo Bioworks | 10-Q: Quarterly report

Ginkgo Bioworks | 10-Q:季度報表
美股sec公告 ·  05/09 16:22
Moomoo AI 已提取核心訊息
Ginkgo Bioworks Holdings, Inc. reported a decrease in total revenue for the first quarter ended March 31, 2024, with revenues falling to $37.944 million from $80.702 million in the same period last year. The company's Cell Engineering segment saw a decrease in revenue from $34.096 million to $27.889 million, while the Biosecurity segment's revenue dropped significantly from $46.606 million to $10.055 million. The total segment operating loss widened to $123.662 million from $116.410 million year-over-year. The diluted net loss per share remained constant at $0.08, improving from a net loss of $0.11 per share in the previous year. Ginkgo Bioworks also reported a net loss of $165.911 million, an improvement from a net loss of $204.969 million in the first quarter of 2023. The company has undertaken restructuring actions to reduce...Show More
Ginkgo Bioworks Holdings, Inc. reported a decrease in total revenue for the first quarter ended March 31, 2024, with revenues falling to $37.944 million from $80.702 million in the same period last year. The company's Cell Engineering segment saw a decrease in revenue from $34.096 million to $27.889 million, while the Biosecurity segment's revenue dropped significantly from $46.606 million to $10.055 million. The total segment operating loss widened to $123.662 million from $116.410 million year-over-year. The diluted net loss per share remained constant at $0.08, improving from a net loss of $0.11 per share in the previous year. Ginkgo Bioworks also reported a net loss of $165.911 million, an improvement from a net loss of $204.969 million in the first quarter of 2023. The company has undertaken restructuring actions to reduce operational expenditures, including labor expense reductions and facility consolidations, expected to commence in the second quarter of 2024. Additionally, Ginkgo acquired platform assets from AgBiome, Inc. on April 10, 2024, to enhance its Ag Biologicals Services. Looking forward, Ginkgo Bioworks aims to leverage its Foundry and Codebase assets to drive scale and learning efficiencies across diverse markets, with a focus on improving the probability of successful product development for its customers.
Ginkgo Bioworks Holdings, Inc.報告稱,截至2024年3月31日的第一季度總收入有所下降,收入從去年同期的8,070.2萬美元降至3794.4萬美元。該公司的細胞工程板塊收入從3,409.6萬美元下降至2789萬美元,而生物安全板塊的收入從4,6606萬美元大幅下降至1,005.5萬美元。該細分市場的總營業虧損從同比1.1641億美元擴大至1.23662億美元。攤薄後的每股淨虧損保持不變,爲0.08美元,高於去年的每股淨虧損0.11美元。Ginkgo Bioworks還報告淨虧損1.65911億美元,較2023年第一季度的淨虧損2.04969億美元有所改善。該公司已...展開全部
Ginkgo Bioworks Holdings, Inc.報告稱,截至2024年3月31日的第一季度總收入有所下降,收入從去年同期的8,070.2萬美元降至3794.4萬美元。該公司的細胞工程板塊收入從3,409.6萬美元下降至2789萬美元,而生物安全板塊的收入從4,6606萬美元大幅下降至1,005.5萬美元。該細分市場的總營業虧損從同比1.1641億美元擴大至1.23662億美元。攤薄後的每股淨虧損保持不變,爲0.08美元,高於去年的每股淨虧損0.11美元。Ginkgo Bioworks還報告淨虧損1.65911億美元,較2023年第一季度的淨虧損2.04969億美元有所改善。該公司已採取重組行動以減少運營支出,包括削減勞動力開支和整合設施,預計將於2024年第二季度開始。此外,Ginkgo於2024年4月10日收購了AgBiome, Inc.的平台資產,以加強其農業生物製品服務。展望未來,Ginkgo Bioworks的目標是利用其Foundry和Codebase資產來提高不同市場的規模和學習效率,重點是提高其客戶成功開發產品的可能性。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息